20D0 Stock Overview A biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cidara Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cidara Therapeutics Historical stock prices Current Share Price US$25.20 52 Week High US$26.20 52 Week Low US$9.20 Beta 0.98 1 Month Change 32.63% 3 Month Change 162.50% 1 Year Change 90.91% 3 Year Change 38.46% 5 Year Change -56.55% Change since IPO -90.91%
Recent News & Updates
Cidara Therapeutics, Inc. Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza Dec 04 Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors Nov 22
Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members Sep 20 Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388 Sep 13
Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer Aug 20
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index Jul 03 See more updates
Cidara Therapeutics, Inc. Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza Dec 04 Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors Nov 22
Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members Sep 20 Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388 Sep 13
Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer Aug 20
Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index Jul 03
Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024 May 26
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules May 17 Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX). Apr 26
Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors
Cidara Therapeutics, Inc. announced delayed annual 10-K filing Apr 03 Cidara Therapeutics, Inc. announced delayed annual 10-K filing Apr 02
Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults Jan 30
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China Dec 06
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id Dec 05 Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel Nov 17
New minor risk - Profitability Nov 06
Forecast to breakeven in 2025 Nov 05
Third quarter 2023 earnings released: US$0.091 loss per share (vs US$0.17 profit in 3Q 2022) Nov 04
Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults Oct 14
Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023 Oct 12
New major risk - Financial position Sep 25
Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development Aug 17
New minor risk - Profitability Aug 07
Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.14 loss in 2Q 2022) Aug 06
Forecast to breakeven in 2025 Aug 06
Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection) Aug 02
New major risk - Share price stability Aug 02
Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B Jun 23
New minor risk - Market cap size Jun 19
Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform Jun 14
First quarter 2023 earnings released: EPS: US$0.032 (vs US$0.27 loss in 1Q 2022) May 14
Full year 2022 earnings released: US$0.43 loss per share (vs US$0.81 loss in FY 2021) Mar 24
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Feb 15
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Jan 26
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform Jan 05
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet Nov 29
High number of new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.17 (vs US$0.36 loss in 3Q 2021) Nov 05
Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market Nov 04
Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Sep 22
Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza Sep 14
Cidara Therapeutics, Inc. Announces Executive Changes Sep 10
Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.18 profit in 2Q 2021) Aug 11
Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Jul 28
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.35 loss in 1Q 2021) May 13
High number of new directors Apr 27
Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile Apr 26
Cidara Therapeutics, Inc. Announces Executive Changes Apr 06
Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza Apr 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 09
Medicines and Healthcare Products Regulatory Agency in the UK Grants Mundipharma and Cidara Therapeutics Inc.'s Rezafungin Promising Innovative Medicine Designation Mar 05
Cidara Therapeutics, Inc. Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza Feb 15
Cidara Therapeutics, Inc. and Mundipharma Announce Positive Topline Results from Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for Treatment of Candidemia and Invasive Candidiasis Dec 15
President recently bought €69k worth of stock Nov 16
Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.41 loss in 3Q 2020) Nov 11
President recently bought €74k worth of stock Aug 22
Cidara Therapeutics and Mundipharma Announces Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis Aug 18
Second quarter 2021 earnings released: EPS US$0.18 (vs US$0.45 loss in 2Q 2020) Aug 14
Chief Financial Officer James Levine has left the company Jul 15
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021 Jul 15 Cidara Therapeutics, Inc.(NasdaqGM:CDTX) dropped from Russell Microcap Value Index
Forecast to breakeven in 2025 May 15
First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.46 loss in 1Q 2020) May 15
Full year 2020 earnings released: US$1.74 loss per share (vs US$1.41 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Cidara Therapeutics, Inc. Announces New Data for Rezafungin At the 21st ICHS Symposium Feb 18
New 90-day high: €2.23 Feb 04
Cidara Therapeutics, Inc. Announces Board Changes Jan 26
Cidara Therapeutics, Inc. Appoints Christopher Kurtz as Executive Vice President of Technical Operations Dec 18
New 90-day low: €1.65 Dec 17
Chief Financial Officer recently bought €85k worth of stock Nov 14
Revenue misses expectations Nov 07
Third quarter 2020 earnings released: US$0.41 loss per share Nov 07 Shareholder Returns 20D0 DE Biotechs DE Market 7D 12.5% 5.8% 2.0% 1Y 90.9% -6.1% 9.6%
See full shareholder returns
Return vs Market: 20D0 exceeded the German Market which returned 9.1% over the past year.
Price Volatility Is 20D0's price volatile compared to industry and market? 20D0 volatility 20D0 Average Weekly Movement 13.2% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 20D0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 20D0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
Show more Cidara Therapeutics, Inc. Fundamentals Summary How do Cidara Therapeutics's earnings and revenue compare to its market cap? 20D0 fundamental statistics Market cap €283.42m Earnings (TTM ) -€119.79m Revenue (TTM ) €43.15m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 20D0 income statement (TTM ) Revenue US$44.65m Cost of Revenue US$66.31m Gross Profit -US$21.65m Other Expenses US$102.30m Earnings -US$123.95m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -11.33 Gross Margin -48.49% Net Profit Margin -277.59% Debt/Equity Ratio 0%
How did 20D0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/07 06:01 End of Day Share Price 2025/01/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cidara Therapeutics, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Timothy Chiang BTIG Chiara Russo Cantor Fitzgerald & Co. Louise Chen Cantor Fitzgerald & Co.
Show 11 more analysts 
